Publications by authors named "Cristian Suarez-Cabrera"

Article Synopsis
  • High-risk non-muscle-invasive bladder cancer (NMIBC) has high rates of recurrence and progression, and there's a need to better understand the tumor microenvironment (TME) for identifying treatment outcome biomarkers.
  • Researchers analyzed TME components and PD-L1 expression in 73 NMIBC patients, finding significant changes in tissue compared to non-tumoral samples, including increased cancer-associated fibroblasts and altered immune cell distributions.
  • The study identified myofibroblasts (myoCAFs) and M2-like macrophages as particularly significant in high-grade NMIBC, with myoCAFs correlating to higher rates of cancer progression and recurrence, providing insights for future prognostic markers.
View Article and Find Full Text PDF

Alterations in the epigenetic machinery in both tumor and immune cells contribute to bladder cancer (BC) development, constituting a promising target as an alternative therapeutic option. Here, we have explored the effects of a novel histone deacetylase (HDAC) inhibitor CM-1758, alone or in combination with immune checkpoint inhibitors (ICI) in BC. We determined the antitumor effects of CM-1758 in various BC cell lines together with the induction of broad transcriptional changes, with focus on the epigenetic regulation of PD-L1.

View Article and Find Full Text PDF

Previous clinical trials have shown that mesenchymal stromal cells (MSCs) can modulate graft versus host disease (GvHD) after allogeneic hematopoietic transplantation, although with variable efficacy. To improve the anti-GvHD effect of these cells, adipose tissue derived-human MSCs (Ad-MSCs) were transduced with a lentiviral vector conferring stable expression of CXCR4, a molecule involved in cell migration to inflamed sites, and IL-10, a cytokine with potent anti-inflammatory properties. experiments showed that the expression of these molecules in Ad-MSCs (named CXCR4-IL10-MSCs) efficiently enhanced their migration towards SDF-1α and also improved their immunomodulatory properties compared to unmodified Ad-MSCs (WT-MSCs).

View Article and Find Full Text PDF

Lung cancer is a malignant disease with high mortality and poor prognosis, frequently diagnosed at advanced stages. Nowadays, immense progress in treatment has been achieved. However, the present scenario continues to be critical, and a full comprehension of tumor progression mechanisms is required, with exosomes being potentially relevant players.

View Article and Find Full Text PDF

Background And Aims: Metastatic urothelial carcinoma (mUC) remains an incurable disease with limited treatment options after platinum-based chemotherapy and immune checkpoint blockade (ICB). Vinflunine has shown a modest increase in overall survival and remains a therapeutic option for chemo- and immunotherapy refractory tumours. However, biomarkers that could identify responding patients to vinflunine and possible alternative therapies after failure to treatment are still missing.

View Article and Find Full Text PDF

Bladder cancer (BC) is the second most frequent cancer of the genitourinary system. The most successful therapy since the 1970s has consisted of intravesical instillations of (BCG) in which the tumor microenvironment (TME), including macrophages, plays an important role. However, some patients cannot be treated with this therapy due to comorbidities and severe inflammatory side effects.

View Article and Find Full Text PDF

is a relatively uncharacterized gene of the Ras superfamily. It is expressed in ES cells and in the first stages of embryonic development; later on, it is silenced in the majority of cell types and tissues. Although there are several reports showing ERAS expression in tumoral cell lines and human tumor samples, it is unknown if ERAS deregulated expression is enough to drive tumor development.

View Article and Find Full Text PDF

Bladder cancer is the most common malignancy of the urinary tract, having one of the highest recurrence rates and progression from non-muscle to muscle invasive bladder cancer that commonly leads to metastasis. Cystoscopy and urine cytology are the standard procedures for its detection but have limited clinical sensitivity and specificity. Herein, a microfluidic device, the UriChip, was developed for the enrichment of urothelial exfoliated cells from fresh and frozen urine, based on deformability and size, and the cancer-associated glycan Sialyl-Tn explored as a putative bladder cancer urinary biomarker.

View Article and Find Full Text PDF

Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer.

View Article and Find Full Text PDF

Odontogenic tumours are a heterogeneous group of lesions that develop in the oral cavity region and are characterized by the formation of tumoural structures that differentiate as teeth. Due to the diversity of their histopathological characteristics and clinical behaviour, the classification of these tumours is still under debate. Alterations in morphogenesis pathways such as the Hedgehog, MAPK and WNT/β-catenin pathways are implicated in the formation of odontogenic lesions, but the molecular bases of many of these lesions are still unknown.

View Article and Find Full Text PDF
Article Synopsis
  • - Bladder cancer (BC) is the most prevalent type of cancer in the urothelial tract, presenting significant challenges due to its high rates of incidence, recurrence, and mortality.
  • - Despite some benefits from immunotherapies, BC remains predominantly incurable, especially in advanced stages, with epigenetic changes like DNA methylation and non-coding RNA alterations playing a critical role in its development.
  • - Recent research highlights the potential of these epigenetic changes as biomarkers and therapeutic targets, offering hope for improved management strategies for bladder cancer in the future.
View Article and Find Full Text PDF

A subpopulation of cancer stem cells (CSCs) with capacity for self-renewal is believed to drive initiation, progression, and relapse of breast tumors. Since the thyroid hormone receptor β (TRβ) appears to suppress breast tumor growth and metastasis, we have analyzed the possibility that TRβ could affect the CSC population using MCF-7 cells grown under adherent conditions or as mammospheres, as well as inoculation into immunodeficient mice. Treatment of TRβ-expressing MCF-7 cells (MCF7-TRβ cells) with the thyroid hormone triiodothyronine (T3) decreased significantly CD44/CD24 and ALDH cell subpopulations, the efficiency of mammosphere formation, the self-renewal capacity of CSCs in limiting dilution assays, the expression of the pluripotency factors in the mammospheres, and tumor initiating capacity in immunodeficient mice, indicating that the hormone reduces the CSC population present within the bulk MCF7-TRβ cultures.

View Article and Find Full Text PDF

Non-muscle invasive bladder cancer (NMIBC) represents a crucial problem for the national health care systems due to its high rates of recurrence and the consequent need of frequent follow-ups. Here, gene expression analyses in patients diagnosed as NMIBC were performed to determine those molecular pathways involved in tumor initiation, finding that both MYC and E2F are up regulated and helps to tumor initiation and progression. Our results also support an important involvement of alternative splicing events, modifying key pathways to favour bladder tumor evolution.

View Article and Find Full Text PDF
Article Synopsis
  • Bladder cancer is particularly deadly in its advanced stages, and recent research has identified new genetic targets and emphasized the limited effectiveness of current treatments, especially immune checkpoint inhibitors.
  • The study highlights how high levels of G9a (EHMT2) expression correlate with worse outcomes and shows that a novel inhibitor, CM-272, can induce cancer cell death and boost immune response when combined with traditional chemotherapy.
  • The combination of CM-272 with immune checkpoint inhibitors demonstrates significant tumor regression and improved immune reactions in a mouse model, suggesting new strategies for treating bladder cancer by pairing epigenetic therapies with immunotherapy.
View Article and Find Full Text PDF

Metabolism reprogramming is considered a hallmark of cancer. The study of bladder cancer (BC) metabolism could be the key to developing new strategies for diagnosis and therapy. This work aimed to identify tissue and urinary metabolic signatures as biomarkers of BC and get further insight into BC tumor biology through the study of gene-metabolite networks and the integration of metabolomics and transcriptomics data.

View Article and Find Full Text PDF

CYLD is a deubiquitinating enzyme known for its role as a tumor suppressor whose mutation leads to skin appendages tumors and other cancers. In this manuscript we report that the tumor suppressor CYLD, similarly to other renowned tumor suppressor genes, protects from premature aging and cancer. We have generated transgenic mice expressing the mutant CYLD protein, lacking its deubiquitinase function, under the control of the keratin 5 promoter, the K5-CYLD mice.

View Article and Find Full Text PDF
Article Synopsis
  • * Lab tests on bladder cancer cell lines showed sensitivity to CDK4/6 inhibitors and identified FOXM1 as a key player in the cancer's response, with the inhibitors reducing FOXM1 phosphorylation and enhancing the effectiveness of cisplatin.
  • * The study suggests that CDK4/6 inhibitors, individually or in combination with cisplatin, could offer a promising new treatment option for patients with advanced bladder cancer who are not suitable for existing therapies.
View Article and Find Full Text PDF

Although Ras genes are frequently mutated in human tumors, these mutations are uncommon in breast cancer. However, many breast tumors show evidences of Ras pathway activation. In this manuscript, we have analyzed and characterized mouse mammary tumors generated by random Sleeping Beauty transposon mutagenesis and identify ERAS -a member of the RAS family silenced in adult tissues- as a new gene involved in progression and malignancy of breast cancer.

View Article and Find Full Text PDF

Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence and recurrence rates, as well as the limited advances in effective disease management. Currently, a combination of cytology and cystoscopy is the routinely used methodology for diagnosis, prognosis and disease surveillance. However, both the poor sensitivity of cytology tests as well as the high invasiveness and big variation in tumour stage and grade interpretation using cystoscopy, emphasizes the urgent need for improvements in BC clinical guidance.

View Article and Find Full Text PDF
Article Synopsis
  • IKKβ is a kinase that mainly boosts the activity of the NF-κB transcription factor but also influences various other cellular processes like metabolism and cell division.
  • The article reviews both the NF-κB-related and other functions of IKKβ, highlighting its complex role in promoting or inhibiting cancer development.
  • It also discusses findings from animal studies and human cancer samples that reveal the connections between IKKβ and cellular transformation.
View Article and Find Full Text PDF
Article Synopsis
  • The article discusses significant findings related to cancer research, specifically addressing advancements in targeted therapies and their implications for treatment outcomes.
  • It also highlights the importance of personalized medicine in improving patient care and reducing side effects from treatments.
  • Additionally, the correction addresses specific data or conclusions that needed clarification or updating to ensure the accuracy of the research presented.
View Article and Find Full Text PDF
Article Synopsis
  • - IKKβ is a protein kinase linked to several cancer signaling pathways, often showing a protumorigenic role in various cancers but displaying a protective role in skin cancer models when overexpressed at the basal skin layer.
  • - Overexpression of IKKβ leads to resistance against skin cancer and increases levels of tumor suppressor proteins like p53, p16, and p19, but its protective effects are unrelated to p53 and depend on a specific locus activity.
  • - The research highlights the dual nature of IKKβ in cancer: it can promote or prevent tumor growth depending on the cellular context, indicating a need for careful evaluation in potential therapeutic targeting of this protein.
View Article and Find Full Text PDF